[{"id":"2d1e326b-a843-4882-b48e-31d0ec882489","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005974","created_at":"2023-08-23T16:10:48.874Z","updated_at":"2024-07-02T16:35:20.791Z","phase":"Phase 2","brief_title":"A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation","source_id_and_acronym":"NCT06005974","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" APC • RAS • AXIN1","pipe":" | ","alterations":" APC mutation","tags":["APC • RAS • AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-4881"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/15/2024","start_date":" 01/15/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-06"}]